In addition, postmortem studies of human MS brains have demonstrated increased BTK expression in MS lesion samples,23 and the use of CNS-penetrating BTK inhibitors in MS clinical trials have shown some promise in phase II trials. Here, BTK is linked to myeloid sarcoma.